Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$250.41

-8.48 (-3.28%)

12:05
05/13/19
05/13
12:05
05/13/19
12:05

Abiomed announces FDA approves label expansion for Impella 5.0 and LD

Abiomed announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days. The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient's hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta. "The expanded indication allows for the opportunity to provide longer duration of support for critically ill patients and a longer period of assessment of heart recovery," the company said.

  • 05

    Jun

  • 13

    Nov

ABMD Abiomed
$250.41

-8.48 (-3.28%)

04/24/19
JEFF
04/24/19
NO CHANGE
Target $460
JEFF
Buy
Abiomed could be pressured on CMS proposed inpatient rates, says Jefferies
The Centers for Medicare and Medicaid Services yesterday issued preliminary hospital inpatient rates that propose a 27% cut to the main Impella code, Jefferies analyst Raj Denhoy tells investors in a research note. Importantly, the proposal does not signal CMS targeting Impella specifically but is formulaic based on cost data CMS is seeing from hospitals, adds the analyst. Also, if recent history is a gauge, final rates will likely settle higher, says Denhoy. Further, he believes notes that rates have little real impact on utilization and that he believes this is already priced into Abiomed shares anyway. The analyst thinks the headline could pressure the stock he stays "firmly" at Buy on Abiomed with a $460 price target.
05/02/19
PIPR
05/02/19
NO CHANGE
Target $320
PIPR
Overweight
Abiomed should be bought after 'surprising' miss, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target for Abiomed to $320 from $480 following the company's "surprising" Q4 miss and reduced outlook. The analyst, still believes in the company and is a buyer of the stock with an unchanged Overweight rating. Abiomed in early trading is down 7%, or $20.47, to $256.60. The primary cause of the shortfall was weakness in the company's protected PCI business, which was negatively impacted by the FDA's cautionary letter to clinicians on Impella RP, O'Brien tells investors in a research note. The analyst, however, believes the totality of "compelling" clinical data will improve utilization of this patient population going forward. He encourages investors to buy the stock on today's weakness.
05/03/19
RHCO
05/03/19
NO CHANGE
Target $340
RHCO
Buy
Abiomed price target lowered to $340 from $450 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Abiomed to $340 after its Q4 revenue miss and below-consensus initial top-line forecasts for FY20. The analyst maintains his Buy rating however and calls the stock a "unique investment opportunity" with a bullish view about the prospects for its "temporary mechanical circulatory support" system.
05/03/19
JEFF
05/03/19
NO CHANGE
Target $330
JEFF
Buy
Jefferies says it's time to own shares of Abiomed
Weakness in Abiomed's fiscal Q4 had been well telegraphed but was still worse than expected, Jefferies analyst Raj Denhoy tells investors in a research note. However, he believes issues with Impella use are being addressed and points out that April saw an uptick from March. The company's fiscal 2020 guidance of 17%-23% "seems doable," adds Denhoy. He lowered his price target for the shares to $330 from $460 and keeps a Buy rating on the name. The analyst believes now is the time to own Abiomed.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$284.59

1.54 (0.54%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Adobe analyst commentary  »

Adobe weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

GLW

Corning

$28.25

-1.79 (-5.96%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Recommendations
Corning analyst commentary  »

Corning shares remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYNH

Syneos Health

$54.63

-0.77 (-1.39%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Conference/Events
Syneos Health management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 27

    Sep

AXSM

Axsome Therapeutics

$28.17

-0.97 (-3.33%)

07:23
09/18/19
09/18
07:23
09/18/19
07:23
Initiation
Axsome Therapeutics initiated  »

William Blair starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

SU

Suncor

$32.14

-0.31 (-0.96%)

07:21
09/18/19
09/18
07:21
09/18/19
07:21
Conference/Events
Suncor management to meet with Morgan Stanley »

Refinery Tour with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NERV

Minerva

$8.09

-0.03 (-0.37%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Initiation
Minerva initiated  »

Minerva initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$138.86

1.25 (0.91%)

07:20
09/18/19
09/18
07:20
09/18/19
07:20
Upgrade
Zimmer Biomet rating change  »

Zimmer Biomet upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

07:20
09/18/19
09/18
07:20
09/18/19
07:20
General news
FX Update: The dollar traded moderately firmer »

FX Update: The dollar…

FDX

FedEx

07:19
09/18/19
09/18
07:19
09/18/19
07:19
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

MTDR

Matador

$17.10

-1.8 (-9.52%)

07:19
09/18/19
09/18
07:19
09/18/19
07:19
Initiation
Matador initiated  »

Matador initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

CBAY

CymaBay

$5.86

-0.02 (-0.34%)

07:17
09/18/19
09/18
07:17
09/18/19
07:17
Recommendations
CymaBay analyst commentary  »

CymaBay CMO change about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:14
09/18/19
09/18
07:14
09/18/19
07:14
Hot Stocks
BeyondSpring expects to submit NDAs for Plinabulin in U.S. in 2020 »

The following outlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

STAG

STAG Industrial

$29.71

-0.055 (-0.18%)

07:14
09/18/19
09/18
07:14
09/18/19
07:14
Conference/Events
STAG Industrial management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

NBY

NovaBay

$0.53

0.0089 (1.72%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Initiation
NovaBay initiated  »

NovaBay initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 09

    Oct

LECO

Lincoln Electric

$89.48

0.38 (0.43%)

07:13
09/18/19
09/18
07:13
09/18/19
07:13
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCSC

Scansource

$30.64

-0.6 (-1.92%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Conference/Events
Scansource management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:12
09/18/19
09/18
07:12
09/18/19
07:12
Hot Stocks
BeyondSpring sees sufficient cash to submit NDAs in China for Plinabulin »

As of June 30, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

FDX

FedEx

$173.53

-0.14 (-0.08%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Recommendations
FedEx analyst commentary  »

FedEx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

  • 17

    Dec

BYSI

BeyondSpring

$19.60

-0.21 (-1.06%)

07:11
09/18/19
09/18
07:11
09/18/19
07:11
Earnings
BeyondSpring reports Q2 EPS (32c), one est. (27c) »

"During the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SBAC

SBA Communications

$252.94

6.55 (2.66%)

07:10
09/18/19
09/18
07:10
09/18/19
07:10
Conference/Events
SBA Communications management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$284.59

1.54 (0.54%)

07:09
09/18/19
09/18
07:09
09/18/19
07:09
Recommendations
Adobe analyst commentary  »

Adobe price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

WLTW

Willis Towers Watson

$198.60

3.52 (1.80%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Hot Stocks
Willis Research Network partners with Mitiga Solutions on aviation initiative »

The Willis Research…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

PM

Philip Morris

$71.98

-0.54 (-0.74%)

, MO

Altria Group

$41.31

-0.1 (-0.24%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Philip Morris, Altria Group analyst commentary  »

Philip Morris, Altria…

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$150.43

0.86 (0.57%)

07:08
09/18/19
09/18
07:08
09/18/19
07:08
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.